All In Biotech

Drug Trial Radar · NCT01096134

Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention

Last checked: Nov 19, 2026Latest source record: Oct 12, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8,000

Actual

Start

Jan 2011

Primary completion

Nov 2012

Study completion Nov 2012

Sponsor

Lead sponsor
JhpiegoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Merck Sharp & Dohme LLC
First posted
Mar 30, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
Who can join
Female only, from 9 years, up to 13 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The Mother-Daughter Initiative (MDI) will test the feasibility and acceptability of a strategy to deliver comprehensive cervical cancer prevention services in Thailand and the Philippines by integrating the HPV vaccine for girls ages 9-13 into already successful screening and treatment programs for mothers.

Conditions

  • Cervical Cancer

Interventions

  • HPV Vaccine (Gardasil)Biological

    HPV Vaccine Administration: According to the CDC, Gardasil should be delivered through a series of three intra-muscular injections over a six-month period. The second and third doses should be given two and six months after the first dose. The vaccine can be administered at the same visit as other age-appropriate vaccines, such as Tdap, Td, MCV4, influenza, and hepatitis B vaccines. Providers should consider a 15-minute waiting period for vaccine recipients following vaccination. FDA's Approval of Gardasil (June 8, 2006) lists the following information on product Formulation: Each 0.5 mL dose of the vaccine contains: 20 mcg of HPV 6 L1 protein 40 mcg of HPV 11 L1 protein 40 mcg of HPV 16 L1 protein 20 mcg of HPV 18 L1 protein 225 mcg aluminum (as amorphous aluminum hydroxyphosphate sulfate adjuvant) 9.56 mg of sodium chloride 0.78 mg of L-histidine 50 mcg of polysorbate 80 35 mcg of sodium borate water for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the population coverage of HPV vaccination of girls aged 9-13 offered within the context of cervical cancer screening and treatment of mothersTime frame: 18 months

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Minglanilla

    Cebu, Philippines

  • Los Banos

    Quezon, Philippines

  • Pagbilao Health Center

    Quezon, Philippines

  • Ban Yuanlae District Health Center

    Ban Phon Ko, Thailand

  • Ban Mai Daeng

    Nakhon Si Thammarat, Nakornsri, Thailand

  • Ban Pai Ta Health Center

    Nakhon Si Thammarat, Nakornsri, Thailand

  • Health promotion Clinic Number 11

    Nakhon Si Thammarat, Nakisron, Thailand

  • Ban Pak Poon Health Center

    Nakhon Si Thammarat, Nakornsri, Thailand

  • Maharat Nakhonsithammarat Primary Care Unit

    Nakhon Si Thammarat, Nakornsri, Thailand

  • Pak-Panung District Health Center

    Nakhon Si Thammarat, Nakornsri, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.